An Open-label Phase 1 Study of ASP4396 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation
Latest Information Update: 23 May 2025
At a glance
- Drugs ASP 4396 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Astellas Pharma
Most Recent Events
- 19 May 2025 According to a Astellas Pharma media release, data from this trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3).
- 26 Apr 2024 Status changed from not yet recruiting to recruiting.
- 18 Apr 2024 New trial record